Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Clin Rheumatol. 2017 Jun;36(6):1445-1451. doi: 10.1007/s10067-017-3600-2. Epub 2017 Mar 13.

Tocilizumab reverses cerebral vasculopathy in a patient with homozygous SAMHD1 mutation.

Author information

1
Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, 45229-3029, USA. michael.henrickson@cchmc.org.
2
DDC Clinic for Special Needs Children, Middlefield, OH, USA.

Abstract

An auto-inflammatory syndrome consequent to SAMHD1 mutations involves cerebral vasculopathy characterized by multifocal stenosis and aneurysms within large arteries, moyamoya, chronic ischemia, and early-onset strokes (SAMS). While this condition involves the innate immune system, additional clinical features mimic systemic lupus erythematosus. Mutations in this gene can also cause a subset of the rare genetic condition Aicardi-Goutières syndrome. To date, no established therapy successfully prevents disease progression. We report a corticosteroid-dependent SAMS patient, a 19-year-old male of Old Order Amish ancestry, with diffuse cerebral arteriopathy identified through contrast brain magnetic resonance arteriography (MRA) and MRI. He received subcutaneous adalimumab every 2 weeks for 9 months with minimal response. Then, he started intravenous tocilizumab (6 mg/kg/dose) every 4 weeks. He sustained steadily normalizing cerebral vasculopathy and lab abnormalities resolved, allowing prednisone reduction. We conclude that the cerebral vasculopathy of the homozygous SAMHD1 mutation-mediated auto-inflammatory disease SAMS responded favorably to tocilizumab infusion therapy.

KEYWORDS:

Aicardi-Goutières syndrome; Cerebral vasculopathy; Moyomoya; SAMHD1 mutation; Tocilizumab

PMID:
28289923
PMCID:
PMC5486483
DOI:
10.1007/s10067-017-3600-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center